Background/Aims: Hyperprolactinaemia is a common endocrine disorder of the hypothalamic-pituitary axis. Its etiology and clinical presentation varies widely, with few studies on this condition reported in Australia, and no available data in North Queensland. The aim of this study is to determine clinical presentation and management options in patients with hyperprolactinemia at The Townsville Hospital (TTH).\ud
\ud
Methods: Medical records of all patients with diagnosed hyperprolactinaemia attending the Endocrinology Clinic at TTH between 2003 and 2013 were retrospectively audited, using outpatient clinic letters. Data analysis evaluated patient demographic data, presenting symptoms, etiology, imaging studies and treatment regimens.\ud
\ud
Results: A total of 153 patients were reviewed with male: female ratio of 1:3. Mean age at diagnosis was 39 + 14.36 years. Menorrhagia was the commonest presenting symptom amongst females (n = 44; 38%), followed by galactorrhea amongst the entire cohort (n=33; 36%). Pituitary adenoma was most of the attributed cause of hyperprolactinaemia (n=92; 60%), 26 being male (28%) and 66 (72%) being female. All patients had magnetic resonant imaging of the pituitary which revealed adenoma in 98% of cases. Medical therapy with dopamine agonist was most prevalent (n= 55; 60%) followed by surgery (n=19; 21%), with (n=7; 8%) of patients received both surgical and medical therapies.\ud
\ud
Conclusion: Prolactinomas constitute a common presentation of hyperprolactinaemia. This audit reflects the prevalence of this condition at TTH Endocrine clinics. Interestingly, galactorrhea was the commonest clinical presenting symptom amongst both sexes. In line with other reports, hyperprolactinaemia was treated with dopamine agonists as preferred primary therapy in majority of the cohort.\u